Dipti Thakkar Email & Phone Number

Singapore

Singapore

Led scientific strategy and operations for a rapidly scaling biotech company, driving breakthrough innovations in antibody therapeutics and precision medicine.Key Achievements:- Provided scientific, strategic and operational leadership for innovative research programs leading to development of multiple first-in-class ADC therapeutics - Contributed to out-licensing deal of next-generation HER3-targeted ADC program- Instrumental in securing Series C financing via generation and strategic presentation of compelling scientific data - Spearheaded development of proprietary biomarker signature for patient selection, now pivotal in clinical trials showing promising efficacy data- Scaled and led multidisciplinary team from 7 to 20+ professionals while maintaining operational excellence

Singapore

Directed comprehensive pre-clinical development strategy, successfully advancing multiple programs from discovery to clinical trials.Key Achievements:- Led development of three first-in-class therapeutic programs through IND-enabling studies to Phase 1: - HMBD-001: Best-in-class anti-HER3 antibody for solid tumors - HMBD-002: First-in-class anti-VISTA antibody - HMBD-115: Novel SARS-CoV-2 therapeutic response- Played a pivotal role in securing extended Series B funding through generations of compelling data aligning with company’s scientific milestones- Successfully navigated regulatory submissions across multiple jurisdictions (MHRA-UK, FDA-USA, HREC-Australia)- Built and led high-performing teams across pharmacology, toxicology, and translational research- Established robust data generation workflows supporting both regulatory filings and investor communications

Singapore

Founding team member instrumental in establishing one of Singapore's largest biotech companies, building R&D capabilities from ground up.Key Achievements:- Part of founding team that established state-of-the-art R&D facility, designing workflows and infrastructure from inception- Built and mentored high-performing discovery team, establishing company's scientific foundation- Contributed to the development of proprietary Rational Antibody Discovery platform, leading to the development of multiple clinical-stage assets- Developed innovative disease-relevant assays and model systems for deep tumor microenvironment profiling- Instrumental in securing transformative partnership with Cancer Research UK for HMBD-001 development and competitive CPRIT grant for HMBD-002 clinical trials

Singapore

Part of the team that was awarded Translational & Clinical Research grant

Banglore

Worked on C. elegans as a model system and successfully built transgenic lines for live imaging

Oxford, Uk

Successfully set up a tissue biobank and undertook the largest GWAS to date in patients with a surgically validated diagnosis of Dupuytren’s disease.